Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025BloodOpen Access

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

View Full Paper
Ask AI
Bookmark
Share

Authors

CPCornelius PauliHeidelberg UniversityMKMichael KienhöferHeidelberg UniversityMBMaximilian Felix BlankHeidelberg University

Discussion

Loading...

Member takes

Overview

Synthetic lethality screens reveal TRMT5's critical role in mitochondrial function in AML, indicating potential new therapeutic strategies.

Key Points

  • Disruption of TRMT5-induced tRNA modifications reduces drug tolerance in leukemia cells, leading to cell death.
  • Systematic CRISPR screens identified the importance of m1G modification for resistance against cytarabine and venetoclax.
  • Targeting TRMT5 shows synergistic effects with existing treatments, increasing efficacy in drug-resistant leukemia models.
  • Correlation between TRMT5 expression and patient outcomes highlights its potential as a therapeutic target in AML.

Cite This Study

Pauli et al. (2025) studied this question.

synapsesocial.com/papers/68c1a8fe54b1d3bfb60e1aaehttps://doi.org/10.1182/blood.2024027822
View Full Paper
Ask AI
Bookmark
Share